A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients With Advanced or Metastatic Renal Cell Carcinoma
Description
Brief Summary
Phase 1b: To evaluate safety and tolerability and determine a recommended phase 2 dose for
TRC105 when added to standard dose axitinib in patients with advanced renal cell carcinoma.
Phase 2: To estimate the PFS of patients with advanced or metastatic RCC by RECIST 1.1
criteria in patients treated with axitinib and TRC105 compared to those treated with
axitinib alone, following failure of one prior VEGF TKI
Phase
N/AInclusion and Exclusion Criteria
Please contact Akshay Bhavsar to learn more about the eligibility criteria for this trial. Please use the contact form on the right side.
Sites
Please contact Akshay Bhavsar to learn more about where you can participate in this trial. Please use the contact form on the right side.
Powered by
SC CTSI